Condition: T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma · Sponsor: Bambino Gesù Hospital and Research Institute
The main purpose of this study is to evaluate the safety, to establish the recommended dose, and to evaluate the antitumor effect of CD7-CART01 in pediatric patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LL).
This description comes directly from the study's public registry record.
Franco Locatelli, MD, PhD · +3966859 · franco.locatelli@opbg.net
Francesca Del Bufalo, MD, PhD · +3966859 · francesca.delbufalo@opbg.net
Always discuss trial participation with your own doctor first.
| Ospedale Pediatrico Bambino Gesù | Rome, Rome, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06064903